Clinical Trial Update: Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CHF6467, a nerve growth factor formulation, for safety and efficacy in patients with optic pathway glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Optic Pathway Glioma

Drugs mentioned

• CHF6467

Snippet

Sponsor: Benedetto Falsini | Conditions: Optic Pathway Glioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING